Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial

BMJ

Volumn 324, Issue 7344, 2002, Pages 1012-

  Chiba, Naoki ^a   Van Zanten, Sander J O Veldhuyzen ^b   Sinclair, Paul ^c   Ferguson, Ralph A ^c   Escobedo, Sergio ^c   Grace, Eileen ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DYSPEPSIA; EMPIRICISM; ERADICATION THERAPY; EVALUATION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BREATH TESTS; CANADA; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0037181736     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7344.1012     Document Type: Article

References (32)

1. Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol 1999; 94: 2845–2854.
2. Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 83–90.
3. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 582–595.
4. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000; 321: 659–664.
5. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361–369.
6. Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori consensus conference update: infections in adults. Can J Gastroenterol 1999; 13: 213–217.
7. Chiba N. Definitions of dyspepsia: time for a reappraisal. Eur J Surg 1998; 164(suppl 583): 14–23.
8. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162(suppl 12): S3–23.
9. Moayyedi P, Carter AM, Catto A, Heppell RM, Grant PJ, Axon AT. Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection. BMJ 1997; 314: 119.
10. Mock T, Yatscoff R, Foster R, Hyun JH, Chung IS, Shim CS, et al. Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Clin Biochem 1999; 32: 59–63.
11. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, Goldie J, Goodacre RL, Riddell RH, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993; 46: 273–279.
12. Junghard O, Lauritsen K, Talley NJ, Wiklund IK. Validation of 7-graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg 1998; 164(suppl 583): 106–111.
13. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407–415.
14. Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten SJO, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998; 164(suppl 583): 41–49.
15. Svedlund J, Sjodin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129–134.
16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Cost benefit analysis. In: Methods for the economic evaluation of health care programmes. New York: Oxford Medical Publications, Oxford University Press, 1997: 205–231.
17. Labour force and unpaid work of Canadians: selected labour force, demographic, cultural, educational and income characteristics by sex (based on the 1991 standard occupational classification) for Canadian provinces, territories and CMAs, 1996 census (20% sample data). Ottawa, Canada: Statistics Canada, 1996.
18. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197–1200.
19. Vinod HD. Bootstrap methods: applications in econometrics. In: MaddalaGS,RaoCR,VinodHD, eds. Handbook of statistics 11: econometrics. Elsevier Science, Chapman and Hall, CRC, 1993: 629–661.
20. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169–1179.
21. Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection [see comments]. Lancet 1995; 345: 1591–1594.
22. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(suppl 2): 37–42.
23. Tytgat GN. GERD remains an intriguing enigma. Gastroenterology 2001; 120: 787.
24. McColl KEL, Dickson A, El-Nujumi A, el-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101–105.
25. Laine L. Helicobacter pylori and complicated ulcer disease. Am J Med 1996; 100: 52–9S.
26. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120–1126.
27. Chiba N, Veldhuyzen van Zanten SJ. 13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection. Can J Gastroenterol 1999; 13: 681–683.
28. Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000; 14: 27–31.
29. Malfertheiner P, on behalf of the European Helicobacter Pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Mäastricht consensus report. Gut 1997; 41: 8–13.
30. Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1–12.
31. Thomson ABR, Armstrong D, Barkun AN, Chiba N, Veldhuyzen van Zanten SJO, Daniels S, et al. Is prompt endoscopy necessary in uninvestigated dyspeptics? Prevalence of upper gastrointestinal abnormalities—the CADET-PE study. Gastroenterology 2001; 120;(suppl 1): A50–A51.
32. Chiba N, Veldhuyzen van Zanten SJO, Grace EM, Sinclair P, Simons WR, Lee JSM. The cost-effectiveness of a test and treat approach in primary care patients. Gut 2000; 47(suppl 1): A113–A114.